Eli Lilly Revenue 2006-2019 | LLY

Eli Lilly annual/quarterly revenue history and growth rate from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Eli Lilly revenue for the quarter ending June 30, 2019 was $5.637B, a 0.93% increase year-over-year.
  • Eli Lilly revenue for the twelve months ending June 30, 2019 was $24.736B, a 10.59% increase year-over-year.
  • Eli Lilly annual revenue for 2018 was $24.556B, a 7.36% increase from 2017.
  • Eli Lilly annual revenue for 2017 was $22.871B, a 7.77% increase from 2016.
  • Eli Lilly annual revenue for 2016 was $21.222B, a 6.33% increase from 2015.
Eli Lilly Annual Revenue
(Millions of US $)
2018 $24,556
2017 $22,871
2016 $21,222
2015 $19,959
2014 $19,616
2013 $23,113
2012 $22,603
2011 $24,287
2010 $23,076
2009 $21,836
2008 $20,372
2007 $18,634
2006 $15,691
2005 $14,645
Eli Lilly Quarterly Revenue
(Millions of US $)
Q2 2019 $5,637
Q1 2019 $5,092
Q4 2018 $7,945
Q3 2018 $6,062
Q2 2018 $5,585
Q1 2018 $4,964
Q4 2017 $6,161
Q3 2017 $5,658
Q2 2017 $5,824
Q1 2017 $5,228
Q4 2016 $5,761
Q3 2016 $5,192
Q2 2016 $5,405
Q1 2016 $4,865
Q4 2015 $5,376
Q3 2015 $4,960
Q2 2015 $4,979
Q1 2015 $4,645
Q4 2014 $5,121
Q3 2014 $4,876
Q2 2014 $4,936
Q1 2014 $4,683
Q4 2013 $5,809
Q3 2013 $5,773
Q2 2013 $5,930
Q1 2013 $5,602
Q4 2012 $5,957
Q3 2012 $5,443
Q2 2012 $5,601
Q1 2012 $5,602
Q4 2011 $6,047
Q3 2011 $6,148
Q2 2011 $6,253
Q1 2011 $5,839
Q4 2010 $6,187
Q3 2010 $5,655
Q2 2010 $5,749
Q1 2010 $5,486
Q4 2009 $5,934
Q3 2009 $5,562
Q2 2009 $5,293
Q1 2009 $5,047
Q4 2008 $5,204
Q3 2008 $5,210
Q2 2008 $5,150
Q1 2008 $4,808
Q4 2007 $5,190
Q3 2007 $4,587
Q2 2007 $4,631
Q1 2007 $4,226
Q4 2006 $4,245
Q3 2006 $3,864
Q2 2006 $3,867
Q1 2006 $3,715
Q4 2005 $3,879
Q3 2005 $3,601
Q2 2005 $3,668
Q1 2005 $3,497
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $104.180B $24.556B
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $337.866B 14.60
Roche Holding AG (RHHBY) Switzerland $251.545B 0.00
Merck (MRK) United States $216.403B 17.79
Pfizer (PFE) United States $201.662B 11.88
Novartis AG (NVS) Switzerland $198.378B 17.07
Novo Nordisk (NVO) Denmark $124.557B 22.01
Sanofi (SNY) France $115.040B 14.14
AstraZeneca (AZN) United Kingdom $114.711B 22.19
AbbVie (ABBV) United States $114.287B 9.16
GlaxoSmithKline (GSK) United Kingdom $106.253B 13.35
Bristol-Myers Squibb (BMY) United States $87.023B 12.34
Bayer (BAYRY) Germany $68.207B 9.94
H Lundbeck (HLUYY) Denmark $6.721B 9.70